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Abstract HIV-1 gp120/gp160 is known to disturb the activity
of p56lck, protein kinase C (PKC) and Ca2+ homeostasis in T
lymphocytes. We found that gp160 decreases the Kv1.3 current
of Jurkat E6.1 cells probably by increasing the PKC-dependent
phosphorylation of Kv channel protein after 5 days. This
decrease is dose-dependent. In contrast, gp160 did not decrease
the Kv1.3 current of the JCaM1.6 cell line, a p56lck-defective
Jurkat cell line. This shows that p56lck was at the beginning of
the events which induced the Kv1.3 current decrease. As a
consequence of this decrease, Jurkat E6.1 cells were depolarized
and exhibited a volume increase.
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1. Introduction
During human immunode¢ciency virus (HIV) infection,
there is an early impairment of T4 cell functions [1,2] followed
by a decrease of the T4 cell number, although only a small
number of these cells in the peripheral blood appears to be
productively infected [3]. The HIV-1 envelope glycoprotein
gp120 is shed from infected cells, and can cross-link the
CD4 receptor of T4 uninfected cells [4,5] leading to T4 lym-
phocyte apoptosis, or anergy, or decreased proliferative re-
sponse after TCR stimulation [6^9], resulting in their progres-
sive disappearance from the blood [3,10]. Thus, HIV-1
modi¢es cytokine patterns and disables the transduction sig-
nal pathways of T cells [11^13]. HIV-1 induces dysfunctions
of Src family protein tyrosine kinase (PTK, p56lck), alterations
of protein kinase C (PKC) and Ca2 homeostasis [14^17].
PKC and Ca2 are known to regulate the voltage-gated
potassium channel activity which is involved in multiple func-
tions of T cells [18,19]. N-type channels (called Kv1.3 chan-
nels since the cloning of the corresponding gene) regulate the
membrane potential (Em) of resting cells (360 mV) and are
implicated in the control of the cell volume [20]. After TCR/
CD3 cross-linking, the Ca2 cytosolic concentration increases,
inhibits Kv1.3 channels and opens K-Ca2-dependent chan-
nels, resulting in membrane hyperpolarization (390 mV [21]).
This hyperpolarization, by maintaining a high driving force
for Ca2, is necessary for the activation process [22]. In con-
trast, the inhibition of Kv1.3 channels depolarizes the cells
and reduces the driving force for Ca2 : in response to a mi-
togenic agent, the proliferation is reduced [23]. Kv1.3 channels
can be inhibited by elements of the TCR signal transduction
pathways: p56lck, PKC and Ca2 [18,19,24,25].
As HIV-1 gp120 disturbs PTKs, PKC and Ca2, three
known inhibitors of Kv1.3 channels, we studied the e¡ects
of cell incubation with gp160, the precursor of gp120 on the
Kv1.3 current, Em value and cell volume.
2. Materials and methods
2.1. Cells
Jurkat E6.1 and JCaM1.6 cells (p56lck-defective Jurkat cells, both
from American Type Culture Collection (ATCC), Rockville, MD,
USA), two CD4 human leukemic T cell lines, were maintained in
RPMI 1640 medium supplemented with 10% fetal calf serum, L-glu-
tamine (20 mM), penicillin (100 U/ml) and streptomycin (50 Wg/ml)
(all from Gibco-BRL, Cergy, France) and incubated at 37‡C in a
humidi¢ed atmosphere containing 5% CO2.
2.2. Solutions and reagents
During patch-clamp experiments, cells were bathed with a Ringer-
like saline solution (in mM): 160 NaCl, 4.5 KCl, 2 CaCl2, 1 MgCl2
and 5 HEPES adjusted to pH 7.4 with NaOH. HIV-1 IIIB gp160
(purity 90%, from NIH, Rockville, MD, USA) was kindly provided
by Dr. Lenaour (CEA, Fontenay aux Roses). 4-Aminopyridine
(4-AP), herbimycin A, staurosporine, 12-O-tetradecanoyl phorbol
13-acetate (TPA) and okadaic acid (OA) were from Sigma. All e¡ec-
tors used were added to the bath.
2.3. Electrophysiology
Experiments were carried out using the whole-cell and the cell-at-
tached recording modes of the patch-clamp [26]. Pipettes, ¢lled with
(in mM) 140 KCl, 5 NaCl, 10 EGTA and 5 HEPES, had a 5^10 M6
resistance. Command potentials were corrected for the junction po-
tential. Membrane currents were recorded with an Axopatch 1-D
ampli¢er (Axon Instruments, Foster City, CA, USA) controlled by
the pClamp 6.0 software (Axon Instruments).
K currents were obtained in the whole-cell con¢guration by ap-
plied 1-s pulses from 3120 to 0 mV in 30-mV steps. The holding
potential was 360 mV. In Fig. 1A, the I/V curves were obtained by
imposing a 500-ms ramp from 3100 to +100 mV.
The Em value was estimated by the method previously described by
Verheugen et al. [27]. A 3200 to +100 mV ramp of 500 ms was
applied in the cell-attached con¢guration. The potential value corre-
sponding to nil current was taken as a measure of 3Em.
Assuming a constant relation of 1 WF/cm2, the membrane capaci-
tance compensation allows the indirect measurement of the cell sur-
face area [26].
2.4. Statistical analysis
Values are means þ S.E.M. Student’s unpaired t-test was performed.
P6 0.05 was considered signi¢cant.
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3. Results and discussion
3.1. Kv1.3 current characterization
Under patch-clamp conditions, Jurkat E6.1 and JCaM1.6
cells exhibited characteristics typical for the N-type outward
K currents due to the Kv1.3 channels from human T lym-
phocytes [28,29]. Both cell types showed the same outward K
current, which was activated at membrane potentials positive
to 340 mV (Fig. 1A), and with an interpulse interval of 30 s
(Fig. 1A,B). In the voltage-step protocol (Fig. 1B), the current
rapidly increased (within 30 ms), followed by an exponential
decrease with a half-inactivation time of 302 þ 9 ms for Jurkat
E6.1 cells, and 327 þ 21 ms for JCaM1.6 cells, at 0 mV pulse.
These currents were inhibited by 1 mM 4-AP (Fig. 1C), 10 mM
TEA-Cl and CsCl (which replaced KCl in the pipette solution)
and by using a 2-s interpulse interval (not shown). During the
5 days of the experiment, the peak amplitude of the Kv1.3
current for 0 mV pulse from both non-treated Jurkat E6.1 and
JCaM1.6 cells was constant (respectively 292 þ 13 pA, n = 130,
and 251 þ 63 pA, n = 20, Fig. 2A,B).
3.2. HIV-1 gp160 treatment and Kv1.3 current
For Jurkat E6.1 cells, HIV-1 gp160 a¡ected the Kv1.3 peak
current in a time- and concentration-dependent manner.
gp160 at 25 Wg/ml, a concentration close to saturation [30],
progressively decreased the Kv1.3 current over 5 days (Fig.
2A). After 6 days, cells became hard to use for patch-clamp
experiments, probably due to membrane structure modi¢ca-
tion. Thus, we analyzed the gp160 e¡ect on Kv1.3 current
after 5 days, at di¡erent concentrations (Fig. 2C). With con-
centrations 6 0.25 Wg/ml, gp160 had no e¡ect on Kv1.3 cur-
rent. In contrast, concentrations s 0.25 Wg/ml decreased the
Kv1.3 current by nearly 40% (P6 0.01). The calculated inhib-
ition constant was 0.353 Wg/ml. A concentration of 25 Wg/ml
had a saturating e¡ect, and was used in all other experiments.
These results indicate that gp160 decreased the Kv1.3 current
only in maximal conditions: at a saturating concentration and
after 5 days. In blood, where a lower concentration of gp160
can be detected [7], the process could be longer, except in
lymphoid organs, where HIV accumulates and replicates ac-
tively despite a low viral burden and low to absent viral rep-
lication in human peripheral blood mononuclear cells
(PBMC) [31]. As shown in Fig. 2D, the Kv1.3 current de-
crease was not due to a current kinetics modi¢cation: the
two traces, one from non-treated, the other from gp160-
treated cells, are perfectly superimposed after normalization
to the peak current. Furthermore, the activation potential
(332 þ 1 mV, n = 9 and 334 þ 1 mV, n = 10) and the half-in-
activation time did not vary (302 þ 9 ms, n = 9 and 297 þ 10,
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Fig. 1. Typical kinetics of Kv1.3 current from Jurkat E6.1 and
JCaM1.6 cells. A: With a ramp protocol, cells exhibited an outward
current for potential s340 mV. B: With a step protocol, cells ex-
hibited A-type current kinetics. C: Application of 4-AP (1 mM) to
the bath inhibited the Kv1.3 current.
Fig. 2. HIV-1 gp160 e¡ect on Kv1.3 peak current from Jurkat E6.1
and JCaM1.6 cells. A: Time-dependent e¡ect of gp160 (25 Wg/ml)
without or with pretreatment by herbimycin A (Herb. A) (10 WM)
on Kv1.3 peak current of Jurkat E6.1 cells at 0 mV, 206 n6 30.
S.E.M. were omitted to clarify the ¢gure, but were between 13 and
32 pA. B: Time-dependent e¡ect of gp160 (25 Wg/ml) on Kv1.3
peak current of JCaM1.6 cells at 0 mV, 56 n6 10,
486S.E.M.6 70 pA. C: Dose-dependent e¡ect of gp160 on Kv1.3
peak current of Jurkat E6.1 cells at 0 mV after 5 days of culture,
n = 10 cells for each point. D: Two Kv1.3 current traces for 0 mV
membrane potential, one from a non-treated, the other from a
gp160-treated Jurkat E6.1 cell, are superimposed after peak normal-
ization. *P6 0.05, signi¢cantly di¡erent from non-treated cell Kv1.3
peak current.
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n = 10, respectively in non-treated and gp160-treated cells). It
is not clear why this process takes 5 days to reach the max-
imal e¡ect. It is interesting to note that during HIV-1 infec-
tion, some phenomena take a long time to work: for example,
Nokta et al. [17] show a PKC activity increase during 24 h
post infection, followed by a net decrease between 4 and
7 days.
In contrast, gp160 (25 Wg/ml) did not a¡ect the Kv1.3 peak
current from JCaM1.6 cells (Fig. 2B). p56lck, a Src family
protein tyrosine kinase, is associated with the CD4 receptor
and is necessary for the TCR/CD3 signal transduction path-
ways [32]. Soula et al. [33] observed a rapid activation of
p56lck following gp160 binding to CD4 on Jurkat cells.
JCaM1.6 cells possess a non-active p56lck, and could not be
activated by TCR/CD3 or CD4 cross-linking [32]. The ab-
sence of an inhibitory e¡ect of gp160 on JCaM1.6 cell
Kv1.3 current shows that p56lck is necessary for the action
of gp160. To con¢rm this result, we used herbimycin A, a
Src family protein tyrosine kinase inhibitor in pretreatment,
before gp160 treatment of Jurkat E6.1 cells. Herbimycin A
(10 WM) did not increase the Kv1.3 current of non-treated
cells in resting conditions (285 þ 23 pA and 305 þ 28 pA, re-
spectively, before and after treatment, n = 5, data not shown);
this shows that in resting conditions Kv1.3 channels are not
tyrosine-phosphorylated. As shown in Fig. 2A, herbimycin A
prevented the Kv1.3 peak current decrease induced by gp160.
P56lck is also associated with the Fas receptor [25]. After Fas/
Fas ligand interaction, p56lck was shown to be activated and
to phosphorylate the Kv1.3 channel proteins, resulting in a
Kv1.3 current decrease [25].
To explain the observed Kv1.3 current decrease of the
5 day-treated Jurkat E6.1 cells by gp160, we hypothesized ¢rst
that this reduction was due to a p56lck-dependent phosphor-
ylation of Kv1.3 channels. In these conditions, when herbimy-
cin A (10 WM) was added for 0.5^1 h before recordings, we
favor tyrosine phosphatase activity, and we did not observe
an increase of Kv1.3 peak current (184 þ 20 pA and 196 þ 25
pA, respectively, before and after treatment, n = 5, data not
shown). Thus, the reduction of Kv1.3 current is probably not
due to p56lck phosphorylation of Kv1.3 channels.
The putative synthesis of a new protein like L subunit is
improbable to explain the Kv1.3 current decrease [34]. Even if
Kv1.3 expressed in Xenopus oocytes were shown to be able to
bind these proteins [34], this binding induces modi¢cations of
the current kinetics characteristics, which was not the case in
the gp160 e¡ect.
A Ca2 inhibition of the Kv1.3 current also seems improb-
able, for two reasons: it should modify the current kinetics
characteristics [18] and we never observed a Kv current run-
up after the whole-cell con¢guration establishment, such as
during Ca2 chelation by the pipette EGTA.
The reduction of the physical number of Kv channels could
be an explanation. During T lymphocyte maturation (thymo-
cytes to active T lymphocyte states), the Kv channel number
could vary from less than 100 to 700 unity [35]. This variation
was not linked to the Kv1.3 mRNA level : in T lymphocytes,
TCR/CD3 cross-link induced a Kv1.3 current increase and a
Kv1.3 mRNA decrease [29]. In Jurkat E6.1 cells, this cross-
link induced a decrease of the Kv1.3 current and the mRNA
rate [29]. This reduction did not modify the current kinetics.
An alternative explanation could be the reduction of the
number of active channels. The protein kinase-dependent
phosphorylation could play a key role in the long-term mod-
ulation of ionic channels observed in various cells, with inhib-
ition or activation e¡ects according to the cell type [36,37].
PKC, whose activity is modi¢ed by gp160 pretreatment [17],
was shown to reduce the N-type current of Jurkat cells with-
out modi¢cation of the current kinetics [19]. Furthermore,
JCaM1.6 cells, which are Jurkat cells with defective p56lck,
were not a¡ected by gp160 treatment (Fig. 2B). Thus, gp160
needed an active signal transduction pathways to reduce the
Kv1.3 current and did probably not directly a¡ect the channel
proteins.
Cai and Douglass [24] showed that PKC or a PKC-like
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Fig. 4. Jurkat E6.1 cells membrane depolarization after 4-AP treat-
ment (A) or HIV-1 gp160 25 Wg/ml (B, n = 15 for each point).
*P6 0.05, signi¢cantly di¡erent from non-treated cell Em.
Fig. 3. E¡ect of phosphorylation-dephosphorylation e¡ectors on
non-treated and gp160-treated Jurkat E6.1 cell Kv1.3 peak current
at 0 mV after 5 days of culture. Stauro = PKC inhibitor,
TPA = PKC activator and OA = protein phosphatase 1 and 2A in-
hibitor. n = 10 for each bar. 3P6 0.05, signi¢cant di¡erence between
non-treated and gp160-treated cell Kv1.3 peak currents in control
conditions. *P6 0.05, signi¢cant di¡erence between corresponding
treatment and control non-treated cell Kv1.3 peak currents.
2P6 0.05, signi¢cant di¡erence between corresponding treatment
and control gp160-treated cell Kv1.3 peak currents.
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enzyme could phosphorylate the Kv1.3 proteins, by using
anti-Kv1.3 antibodies. Unfortunately, the presence of signi¢-
cant levels of endogenous PKC partly phosphorylated Kv1.3
proteins. Thus, they observed that a PKC activity increase, by
addition of exogenous PKC, had little e¡ect on Kv1.3 phos-
phorylation detected by anti-Kv1.3 antibodies. In our case, we
used the patch-clamp technique to study the e¡ect of PKC
activity change on Kv1.3 current from non-treated and gp160-
treated Jurkat E6.1 cells (25 Wg/ml, 5 days).
In non-treated cells, staurosporine, a PKC inhibitor [19],
increased the Kv1.3 current by 60% (Fig. 3). Staurosporine
allowed the complete dephosphorylation of the channel pro-
tein [38]. Thus, in control conditions, one third of the Kv1.3
channels was ‘disconnected’. In gp160-treated cells, stauro-
sporine increased the Kv1.3 current by 164% and to an am-
plitude similar to that obtained with non-treated cells.
This result suggests that gp160-treated cells possess the
same number of Kv1.3 channels as non-treated cells (same
current amplitude after dephosphorylation) and that the ob-
served current di¡erence is due to an increase of the channel
phosphorylation rate. This increase may be due to a more
active phosphorylation process, or a less active dephosphor-
ylation process. Staurosporine, by inhibiting the PKC activity,
makes it possible to observe the phosphatase activity. The fact
that staurosporine treatment results in the same current am-
plitude in non-treated and gp160-treated cells leads to the
supposition that the dephosphorylation activity is intact.
Thus, in gp160-treated cells, two thirds of Kv1.3 channels
are phosphorylated.
TPA, a PKC activator [19], half-decreased the non-treated
cells Kv1.3 current, to an amplitude closed to the gp160-
treated amplitude current (Fig. 3). OA, a phosphatase inhib-
itor, did likewise (Fig. 3), which favors that phosphorylation
of channel protein by PKC decreased the current at the same
rate. In contrast, TPA and OA had no e¡ect on Kv1.3 current
from treated cells (Fig. 3). These results suggest that in gp160-
treated cells, the Kv1.3 channels could be up-phosphorylated
by PKC in comparison with non-treated cells. These results
are partly in opposition with a previous work which described
a PKC activity increase after 24 h of HIV infection, followed
by a decrease after a longer time in lymphocytes [17]. Our
experiments were done without infection, and we may hy-
pothesize that other viral proteins could modulate PKC activ-
ity or induce a reduction of the protein number. Thus, a
HIV-1 gp41 derivative polypeptide was shown to inhibit
PKC activity and PKC-dependent immune function in human
PBMC [39].
3.3. Membrane potential value and cell size variation of Jurkat
E6.1 following HIV-1 gp160 treatment
To verify that Kv1.3 channels are implicated in Em regula-
tion, we tested the e¡ect of 4-AP on Em value. 4-AP, a volt-
age-dependent K channel blocker [40], induced a net depo-
larization of Jurkat E6.1 cells (vEm =340 mV, Fig. 4A) and
we show that it completely inhibited the Kv1.3 current (Fig.
1C). These results con¢rm that the Kv1.3 current is implicated
in Em value control. Without reagent, the Em value was con-
stant during the 5 days of the experiments (Fig. 4B). This
value (mean =367.3 þ 3.2 mV, n = 23) is in agreement with
those obtained on T lymphocytes with the same technique
[27] and with £uorescent probes [21,23]. Addition of gp160
to the cell culture signi¢cantly decreased the Em value
(vEm = 10.6 mV, P6 0.05) after 24 h (Fig. 4B). After the
following 5 days, the depolarization increased slightly
(vEm = 16.1 mV, P6 0.01). The fact that the observed depo-
larization appeared rapidly shows that in gp160-treated cells,
Kv1.3 channels were not the sole Em value controller. Thus,
the opening of anionic channels is known to be depolarizing
[20]. The proliferative response is largely dependent on the Em
value. Like charybdotoxin-induced depolarization [23], the
observed gp160-induced depolarization could result in a de-
creased proliferation after TCR/CD3 cross-linking, by reduc-
ing the Ca2 driving force.
Like the Em value, gp160 treatment of Jurkat cells modi¢es
their size. The non-treated cells had a cell surface of 627 þ 21
Wm2 (n = 130), and were constant in size during the 5 days of
measuring (Fig. 5). The gp160-treated cell size increased sig-
ni¢cantly by 25% only after 5 days, corresponding to a 40%
volume increase, and seemed to follow the Kv1.3 current de-
crease (Fig. 5). In fact, cell volume is an equilibrium between
shrinking and swelling [41]. Thus, the two process are con-
comitant. Kv and Cl channels, by their opening, allow the cell
to shrink, by a net loss of KCl and water [20]. We hypothesize
that gp160, by reducing the Kv current, does not allow the
necessary e¥ux of K and the reduction of cell volume.
In conclusion, we show that HIV-1, without infection and
only by the interaction of its envelope glycoprotein gp160
with the CD4 receptor on T cell surface, can induce ‘mem-
brane disorder’ by up-phosphorylation of the Kv1.3 channel
proteins and membrane depolarization, in addition to ‘cyto-
plasmic disorders’ (modi¢ed PKC activity, altered Ca2 con-
centration variation). It seems that gp160 acts in a di¡erent
way on Jurkat E6.1 cells compared to the e¡ect of gp120 on
astrocytes [42], even if the result in both cases is a progressive
depolarization. In astrocytes, this depolarization leads to the
opening of Ca2 voltage-gated channels and results in cell
death by Ca2 neurotoxicity [42]. In contrast, in Jurkat E6.1
cells, this depolarization probably reduces the Ca2 driving
force and the proliferation.
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